Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation

Bone Marrow Transplantation

Volumn 20, Issue 11, 1997, Pages 961-963

  Oblon, D J ^a   Paul, S R ^b   Oblon, M B ^a   Malik, S ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

High dose etoposide; Mucositis; Supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPANTHELINE BROMIDE;

ADULT; ARTICLE; AUTOGRAFT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXCRETION; DRUG SALIVA LEVEL; ENTERITIS; ESOPHAGITIS; FEMALE; HEART PALPITATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TACHYCARDIA; URINE RETENTION; XEROSTOMIA;

EID: 0030727026     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701006     Document Type: Article

References (14)

1. Wolf SN, Fev M, McKay CM et al. High dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a Phase I study. J Clin Oncol 1983; 1: 701-705.
2. Brown RA, Herzig RH, Wolf SN et al. High dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancies. Blood 1990; 76: 473-479.
3. Ahmed T, Ciavarella D, Feldman E et al. High dose, potentially myeloablative chemotherapy for patients with advanced Hodgkin's disease. Leukemia 1989; 3: 19-22.
4. Jagganth S, Dicke KA, Armitage JO et al. High dose cyclophosphamide, carmustine and etoposide and autologous transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163-168.
5. Wilkes GM. Sucralfate suspension for mucositis. Oncol Nursing Forum 1986; 13: 71.
6. Ahmed T, Engelking C, Szalyga J et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993; 12: 131-132.
7. Engelking C. Managing stomatitis: a nursing management approach. In: Moore P (ed). Supportive Care for the Patient with Cancer. Medical Marketing Interaction: Valley Cottage, New York, 1988; pp 20-23.
8. Fields KK, Elfenbein GJ, Lazarus HM et al. Maximum tolerated doses of ifosfamide, carboplatin and etoposide given over six days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323-332.
9. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. New Engl J Med 1988; 318: 1414-1422.
10. Sheridan W, Morstyn G, Wolf M et al. Granulocyte stimulating factor and neutrophil recovery following high dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; ii: 891-895.
11. Lieschke GJ, Ramenjhi U, O'Connor MP et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 1992: 82: 589-595.
12. Yuhas JM. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979; 63: 971-976.
13. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by SR-2721. Cancer Res 1982; 42: 4330-4331.
14. Tanaka Y. Clinical experiences with a chemical radioprotector in tumor radiotherapy: WR 2721. In: Sugahara T (ed). Modification of Radiosensitivity in Cancer Treatment. Academic Press Japan, Inc: Tokyo, 1984, pp 61-81.